RESEARCH · NAD+
NAD+: Coenzyme Biology, CD38 and PARP Consumption, and the Open Questions on Delivery
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to energy metabolism. It is not a peptide, and that matters for how it is studied and handled. Our short post What is NAD+ 500mg at PurixLab is a product FAQ; this article is a literature overview of what the peer-reviewed record reports about NAD+ biology, and where the evidence is thin. PurixLab’s NAD+ 500mg is supplied as a research material for laboratory research use only.
Two jobs: coenzyme and substrate
NAD+ is a coenzyme for redox reactions, which makes it central to energy metabolism. It is also an essential cofactor for non-redox enzymes, including sirtuins, CD38 and poly(ADP-ribose) polymerases (PARPs), and through them it influences DNA repair, chromatin remodelling, cellular senescence and immune-cell function [1]. Unlike a redox cycle, these enzymes consume NAD+: PARPs, SARM1, sirtuins and CD38 all break it down while carrying out their signalling roles [2]. Cellular NAD+ levels therefore reflect a balance between biosynthesis and consumption.
CD38: an NAD+-consuming enzyme that rises with age in mice
In mice, the NADase CD38 increased in expression and activity with ageing, and was required for the age-related NAD decline and mitochondrial dysfunction, partly through SIRT3. The same study identified CD38 as the main enzyme degrading the precursor nicotinamide mononucleotide (NMN) in vivo [3]. A later study found that the rise of CD38 in white adipose tissue and liver during ageing is mediated by accumulation of CD38-positive immune cells, that senescent cells promote this accumulation, and that blocking CD38’s ecto-enzymatic activity increased NAD+ through an NMN-dependent process [4].
PARP1: consumption after DNA damage
In cultured cells, laser-induced nuclear DNA damage triggered PARP-dependent NAD+ depletion, a rapid cell-wide increase in the bound NADH fraction and a move toward oxidative phosphorylation. Inhibiting oxidative phosphorylation, but not glycolysis, led to parthanatos (a form of cell death) through rapid PARP-dependent ATP deprivation [5]. Reviewers summarise the ageing picture as an imbalance between biosynthesis and consumption, with reduced NAMPT (the rate-limiting biosynthetic enzyme) and increased PARP and CD38 activity [2].
Does NAD+ really decline with age in humans?
Reviews state that tissue NAD+ declines with age in several organisms, including humans [1,2]. The human evidence is less settled. A 2025 review noted that an age-related decline has been consistently observed in only a limited number of human studies, that published data on NAD+ dynamics in human tissues remain sparse, and that extrapolating from rodents is not straightforward [6]. A 2026 analysis of seven independent human cohorts, using a validated mass-spectrometry method, found whole-blood NAD+ stable with age and across lifestyle interventions, while it did change with nicotinamide riboside (NR) supplementation; the authors question blood NAD+ as an ageing biomarker [7].
Precursor studies are not NAD+ studies
Most human work uses oral precursors rather than NAD+ itself. In a placebo-controlled crossover trial in healthy middle-aged and older adults, chronic NR supplementation was well tolerated and stimulated NAD+ metabolism [8]. Yet the 2025 review concluded that human trials have shown limited efficacy so far [6], and an Endocrine Reviews appraisal says the clinical pharmacology, metabolism and mechanisms of NAD+ precursors remain incompletely understood and calls for adequately powered randomised trials [9]. These findings concern precursors in human volunteers; they are not statements about any laboratory reagent.
What happens to NAD+ outside the cell?
- Cell culture. In human HEK293 cultures containing serum, mono- and dinucleotides were degraded to nucleosides and then bases, and degradation also occurred in medium alone, indicating enzymatic activity in the serum. Experiments with transporter inhibitors indicated that extracellular cleavage of NAD+ and NMN to NR is a prerequisite for maintaining intracellular NAD [10].
- Homeostatic resetting. After prolonged extracellular NAD+ exposure, intracellular NAD+ first rose and then fell back to control levels, because uptake of cleaved products was reduced through a SIRT1-dependent response [11].
- A human pilot. A small pilot study reported that directly infused NAD+ was rapidly and completely removed from plasma for at least two hours, with a metabolite profile consistent with glycohydrolase and pyrophosphatase activity [12].
- Compartments and pathways. A 2024 review stresses distinct subcellular NAD+ pools, microbiome effects on precursor availability and non-canonical degradation pathways, and argues that much of the basic biology still needs to be mapped [13].
What remains unknown
- Whether NAD+ decline is a general feature of human ageing, and in which tissues [6,7].
- Whether raising NAD+ levels produces functional benefit in humans; trials so far show limited efficacy [6,9].
- How extracellular NAD+ is converted, taken up and compartmentalised, and how that differs between NAD+ and its precursors [10,11,13].
- The identity, purity and stability of any specific material. Published biology says nothing about a given vial, so batch documentation matters. NAD+ is a dinucleotide rather than a peptide, so peptide-oriented storage guides do not map directly onto it; follow the product label and your laboratory’s approved procedures.
NAD+ 500mg at PurixLab
NAD+ 500mg: a labelled research vial with 500mg per vial, C$109 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/nad-500mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Codes: WELCOME10 takes 10% off eligible orders below C$400; PURIX20 takes 20% off eligible orders of C$400 or more before discount and tax. One offer per order; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Covarrubias AJ, Perrone R, Grozio A, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141. PubMed 33353981 · PMC7963035 · doi:10.1038/s41580-020-00313-x
- Strømland Ø, Diab J, Ferrario E, et al. The balance between NAD+ biosynthesis and consumption in ageing. Mech Ageing Dev. 2021;199:111569. PubMed 34509469 · doi:10.1016/j.mad.2021.111569
- Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-1139. PubMed 27304511 · PMC4911708 · doi:10.1016/j.cmet.2016.05.006
- Chini CCS, Peclat TR, Warner GM, et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels. Nat Metab. 2020;2(11):1284-1304. PubMed 33199925 · PMC8752031 · doi:10.1038/s42255-020-00298-z
- Murata MM, Kong X, Moncada E, et al. NAD+ consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival. Mol Biol Cell. 2019;30(20):2584-2597. PubMed 31390283 · PMC6740200 · doi:10.1091/mbc.E18-10-0650
- Vinten KT, Trętowicz MM, Coskun E, et al. NAD+ precursor supplementation in human ageing: clinical evidence and challenges. Nat Metab. 2025;7(10):1974-1990. PubMed 41083806 · doi:10.1038/s42255-025-01387-7
- Trętowicz MM, Scantlebery AML, Schomakers BV, et al. Human whole-blood NAD+ levels do not vary with age or lifestyle interventions. Nat Metab. 2026;8(6):1282-1290. PubMed 42135539 · doi:10.1038/s42255-026-01537-5
- Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PubMed 29599478 · PMC5876407 · doi:10.1038/s41467-018-03421-7
- Bhasin S, Seals D, Migaud M, et al. Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns. Endocr Rev. 2023;44(6):1047-1073. PubMed 37364580 · PMC12102727 · doi:10.1210/endrev/bnad019
- Kulikova V, Shabalin K, Nerinovski K, et al. Degradation of Extracellular NAD+ Intermediates in Cultures of Human HEK293 Cells. Metabolites. 2019;9(12):293. PubMed 31795381 · PMC6950141 · doi:10.3390/metabo9120293
- Buonvicino D, Ranieri G, Pittelli M, et al. SIRT1-dependent restoration of NAD+ homeostasis after increased extracellular NAD+ exposure. J Biol Chem. 2021;297(1):100855. PubMed 34097876 · PMC8233143 · doi:10.1016/j.jbc.2021.100855
- Grant R, Berg J, Mestayer R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci. 2019;11:257. PubMed 31572171 · PMC6751327 · doi:10.3389/fnagi.2019.00257
- Migaud ME, Ziegler M, Baur JA. Regulation of and challenges in targeting NAD+ metabolism. Nat Rev Mol Cell Biol. 2024;25(10):822-840. PubMed 39026037 · PMC12456757 · doi:10.1038/s41580-024-00752-w